uploads/2017/12/Brilinta.png

AstraZeneca’s Brilinta and Farxiga Posted High Growth in 3Q17

By

Updated

Brilinta’s revenue trends

In 3Q17, AstraZeneca’s (AZN) Brilinta generated revenues of $284.0 million, which reflected ~37.0% growth on a year-over-year (or YoY) basis and 4.0% growth on a quarter-over-quarter basis.

Brilinta reported 9M17 revenues of $780.0 million, which represents ~29.0% growth on a YoY basis.

Brilinta generated 9M17 revenues of ~$175.0 million from emerging markets, which reflected 29.0% YoY growth. In the US, Brilinta reported 9M17 revenues of $355.0 million, reflecting 46.0% YoY growth.

New favored guidelines from the American College of Cardiology and the American Heart Association in 2016 primarily attributed to the increased demand for Brilinta in the US market.

Brilinta is used to decrease the rate of cardiovascular death, myocardial infarction, and stroke in individuals with an acute coronary syndrome or having a history of myocardial infarction. Brilinta competes with Bristol-Myers Squibb’s (BMY) and Sanofi’s Plavix.

Farxiga’s revenue trends

Farxiga (dapagliflozin) is used for the treatment of adults with type 2 diabetes mellitus. In 3Q17, Farxiga generated revenues of $285.0 million, which represents ~30.0% growth on a YoY basis and 14.0% growth on a quarter-over-quarter basis. Farxiga reported 9M17 revenues of $742.0 million, which is ~24.0% growth on a YoY basis.

In the emerging markets, the US, and Europe in 9M17, Farxiga generated revenues of $160.0 million, $339.0 million, and $171 million, respectively, reflecting ~74.0%, ~4.0%, and 26.0% YoY growth.

In June 2017, AstraZeneca presented new data on the safety profile of Farxiga at the American Diabetes Association’s 77th Scientific Sessions. The updated safety data analysis consisting of data consolidated from 30 Phase 2b/3 clinical trials on Farxiga demonstrated no new safety signals. The incidence of adverse events for Farxiga was similar to that of the control groups.

Farxiga’s peers in the antidiabetes drugs market include Eli Lilly’s (LLY) Jardiance and Johnson & Johnson’s (JNJ) Invokana. AstraZeneca comprises ~0.33% of the Vanguard International High Dividend Yield ETF’s (VYMI) portfolio.

More From Market Realist